BACKGROUND: Arsenic trioxide (ATO) has demonstrated preclinical evidence of activity in the treatment of infiltrating astrocytomas. METHODS: We conducted a phase I trial of ATO given concomitantly with radiation therapy in children with newly diagnosed anaplastic astrocytoma, glioblastoma, or diffuse intrinsic pontine glioma. Eligible patients received a fixed daily dose of 0.15 mg/kg of ATO once a week, with each subsequent cohort of patients receiving an additional dose per week up to a planned frequency of ATO administration 5 days per week as tolerated. Twenty-four children were enrolled and 21 children were evaluable. RESULTS: ATO was well tolerated throughout the entire dose escalation, resulting in confirmation of safety when administered 5 days per week during irradiation. CONCLUSIONS: The recommended dose of ATO during conventional irradiation is 0.15 mg/kg given on a daily basis with each fraction of radiation therapy administered.
BACKGROUND:Arsenic trioxide (ATO) has demonstrated preclinical evidence of activity in the treatment of infiltrating astrocytomas. METHODS: We conducted a phase I trial of ATO given concomitantly with radiation therapy in children with newly diagnosed anaplastic astrocytoma, glioblastoma, or diffuse intrinsic pontine glioma. Eligible patients received a fixed daily dose of 0.15 mg/kg of ATO once a week, with each subsequent cohort of patients receiving an additional dose per week up to a planned frequency of ATO administration 5 days per week as tolerated. Twenty-four children were enrolled and 21 children were evaluable. RESULTS:ATO was well tolerated throughout the entire dose escalation, resulting in confirmation of safety when administered 5 days per week during irradiation. CONCLUSIONS: The recommended dose of ATO during conventional irradiation is 0.15 mg/kg given on a daily basis with each fraction of radiation therapy administered.
Authors: Elspeth M Beauchamp; Lymor Ringer; Gülay Bulut; Kamal P Sajwan; Michael D Hall; Yi-Chien Lee; Daniel Peaceman; Metin Ozdemirli; Olga Rodriguez; Tobey J Macdonald; Chris Albanese; Jeffrey A Toretsky; Aykut Uren Journal: J Clin Invest Date: 2010-12-22 Impact factor: 14.808
Authors: C Tomuleasa; O Soritau; G Kacso; E Fischer-Fodor; A Cocis; H Ioani; T Timis; M Petrescu; D Cernea; P Virag; A Irimie; I S Florian Journal: J BUON Date: 2010 Oct-Dec Impact factor: 2.533
Authors: Shakeel Modak; Pat Zanzonico; Jorge A Carrasquillo; Brian H Kushner; Kim Kramer; Nai-Kong V Cheung; Steven M Larson; Neeta Pandit-Taskar Journal: J Nucl Med Date: 2016-01-07 Impact factor: 10.057